Poland· PL-100532274

Otrivin ipra MAX

A xylometazoline product containing xylometazolini hydrochloridum + ipratropii bromidum, registered in Poland by Medezin Sp. z o.o.. The same ATC class is registered in 10 of our 19 countries.

ATC R01AB06

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedOtrivin ipra MAXATCR01AB06REGISTER NO.PL-100532274PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Xylometazoline is registered in 10 of 19 countries.

Countries holding a registration under ATC R01AB06 (xylometazoline), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Xylometazoline · ATC R01AB06

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Xylometazolini hydrochloridum + Ipratropii bromidum
Manufacturer
Medezin Sp. z o.o.
Country
Poland (PL)
ATC code
R01AB06
ATC class
Xylometazoline
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991593445
  • gtin
    05909991593452

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

63 interactions on record for xylometazoline.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Xylometazoline · interactions on record

63 records

  • 6 severe
  • 54 moderate

Most severe, free to view

  • MethylergometrineG02AB01severe
  • DihydroergotamineN02CA01severe
  • ErgotamineN02CA02severe
  • MethysergideN02CA04severe

3 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Xylometazoline in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All xylometazoline products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Otrivin Duo
  • Belgium · Otrivine Duo
  • Cyprus · Otrivin Advance
  • Czechia · Otrivin Duo
  • Denmark · Otrivin Comp, Zymelin Plus
  • Estonia · Otrivin Total
  • Spain · Rhinovin Duo
  • Finland · Otrivin Comp
  • United Kingdom (Northern Ireland) · Otrivine Extra Dual Relief
  • Greece · Otrivin Advance
  • Croatia · Ksilometazolinklorid/Ipratropijev Bromid Acino, Nasoryl
  • Hungary · Otrivin Komplex
  • Ireland · Otrivine Extra Dual Relief
  • Iceland · Otrivin Comp
  • Italy · Rinazina Doppia Azione
  • Lithuania · Otriduo
  • Luxembourg · Otrivine Duo
  • Latvia · Otrivin Total
  • Malta · Otrivine Extra Dual Relief
  • Netherlands · Otrivin Duo
  • Norway · Otrivin Comp, Zycomb
  • Portugal · Nasitrim Duoeffect, Vibrocil Actilongduo
  • Romania · Rhinxyl Plus, Vibrocil Duo
  • Sweden · Otrivin Comp, Zymelin Comp
  • Slovenia · Maresyl Comb, Otrivin Duo
  • Slovakia · Otrivin Duo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fac2e032-b599-4b2a-b4b1-e2c028d8c1ac
GET /v1/drugs/fac2e032-b599-4b2a-b4b1-e2c028d8c1ac?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Aerozol do nosa, roztwór",
  "source": "urpl",
  "strength": "(0,5 mg + 0,6 mg)/ml",
  "packaging": "05909991593445 ¦ OTC ¦ 165600\n1 butelka 10 ml (butelka z pompką dozującą uruchamianą pionowo)\n05909991593452 ¦ OTC ¦ 165601\n1 butelka 10 ml (butelka z pompką dozującą uruchamianą z boku)",
  "substance": "Xylometazolini hydrochloridum 0.5 mg/ml + Ipratropii bromidum 0.6 mg/ml",
  "common_name": "Xylometazolini hydrochloridum + Ipratropii bromidum",
  "pl_product_id": "100532274",
  "pozwolenie_nr": "045/26",
  "auth_procedure": "IR",
  "authorisation_validity": "2031-01-28"
}

See everything about xylometazoline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.